Mobility assessment using wearable technology in patients with late-onset Pompe disease.

Abstract

Late-onset Pompe disease (LOPD) is a rare genetic disorder due to the absence or deficiency of acid alpha-glucosidase enzyme resulting in slowly progressing reduction of muscle strength, causing difficulties with mobility and respiration. Wearable technologies offer novel options to evaluate mobility in a real-world setting. LOPD patients self-reporting LOPD, ≥18 years, US residents, walking (with or without aid), and not on invasive ventilation were recruited for a 6- to 8-week wearable study via patient organizations. Eligible patients were shipped a wearable tracker (Fitbit One™) and completed self-assessment questionnaires. Mobility outcome measures were median step count and peak 1-min activity. In the analyses cohort (<i>N</i> = 29), engagement in data sharing was high (94% of patients uploaded data for more than half the study days). Mean age was 43 years, 90% were females, and 93% were diagnosed in adulthood. Mean delay in diagnosis was 10 years; most had disease onset for ≥10 years (55%); some required walking aid (17%) and breathing assistance (38%). Mean step count differed by age (20-39 years: 4071 vs. 40-69 years: 2394, <i>p</i> < 0.01), diagnostic delay (<10 years: 3584 vs. ≥10 years: 2232, <i>p</i> < 0.05), disease duration (<10 years: 4219 vs. ≥10 years: 2462, <i>p</i> < 0.05), and ambulatory status (aided: 1883 vs. unaided: 3408, <i>p</i> < 0.05). Patient-reported "fatigue and pain" score was inversely correlated with step count (Pearson's <i>r</i> = -0.42, <i>p</i> < 0.05) and peak 1-min activity (Pearson's <i>r</i> = -0.49, <i>p</i> < 0.01). This study illustrates a new approach to measure mobility in LOPD patients and establishes a framework for future outcomes data collection.